Uploaded June 2026 | Updated September 2026, 3 weeks ago
"The number on the scale doesn't matter — what matters is my health." It's one of the most common refrains in GLP-1 communities. And there's real truth to it. But there's also a version of that framing that doesn't serve people well.
In this video, I break down what the research actually shows — including emerging evidence that GLP-1 medications like semaglutide do improve health through direct biological effects independent of weight loss, in areas like cardiovascular health, liver disease, and kidney function. That's real, it matters, and it deserves to be part of the conversation.
But I also make the case that weight loss — specifically fat loss, specifically visceral fat loss — is still where the biggest health gains come from. And that there's a critically underappreciated piece almost nobody in these communities talks about: not all weight loss is the same. Losing muscle while on a GLP-1 is a real risk, and the composition of what you're losing matters enormously for your long-term metabolic health.
This isn't a judgment. It's a nuance reframe — one that I think actually serves people on these medications better than either extreme.
📌 What's covered:
– Where "health not weight" comes from, and why it resonates
– The SELECT trial, FLOW trial, STEP 1, and what they actually show
– New research on GLP-1s improving liver and kidney health independently of weight loss
– The two-tier benefit model: what the drug does on its own vs. what fat loss adds
– Why body composition — not just the scale — is the metric that matters most
– The lean mass problem: 35–40% of weight lost on GLP-1s can be muscle
– What a truly successful GLP-1 journey looks like in practice
SOURCES
SELECT Trial — Lincoff et al., NEJM 2023 — Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes
SELECT Adiposity Analysis — Deanfield et al., The Lancet 2025 — Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements
SELECT Long-Term Weight Data — Ryan et al., Nature Medicine 2024 — Long-term weight loss effects of semaglutide in SELECT
SELECT Kidney Outcomes — Nature Medicine 2024 — 22% reduction in kidney outcomes in the SELECT cohort
STEP 1 Trial — Wilding et al., NEJM 2021 — Once-Weekly Semaglutide in Adults with Overweight or Obesity
FLOW Trial — Perkovic et al., NEJM 2024 — Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
GLP-1 Liver Mechanisms — Drucker et al., Cell Metabolism 2026 — Semaglutide acts directly on liver sinusoidal endothelial cells independent of weight loss
Cardiovascular Meta-analysis — PMC 2025 — Long-Term Cardiovascular Outcomes of GLP-1 Receptor Agonists in Non-diabetic Obesity
Lean Mass / GLP-1 Meta-analysis — Metabolism: Clinical and Experimental, 2024 — Effect of GLP-1 receptor agonists and co-agonists on body composition
COURAGE Trial (Regeneron) — Interim results, 2024 — Semaglutide-induced weight loss composition data
Visceral Fat Meta-analysis — PLOS ONE, 2023 — Effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
"The number on the scale doesn't matter — what matters is my health." It's one of the most common refrains in GLP-1 communities. And there's real truth to it. But there's also a version of that framing that doesn't serve people well.
In this video, I break down what the research actually shows — including emerging evidence that GLP-1 medications like semaglutide do improve health through direct biological effects independent of weight loss, in areas like cardiovascular health, liver disease, and kidney function. That's real, it matters, and it deserves to be part of the conversation.
But I also make the case that weight loss — specifically fat loss, specifically visceral fat loss — is still where the biggest health gains come from. And that there's a critically underappreciated piece almost nobody in these communities talks about: not all weight loss is the same. Losing muscle while on a GLP-1 is a real risk, and the composition of what you're losing matters enormously for your long-term metabolic health.
This isn't a judgment. It's a nuance reframe — one that I think actually serves people on these medications better than either extreme.
📌 What's covered:
– Where "health not weight" comes from, and why it resonates
– The SELECT trial, FLOW trial, STEP 1, and what they actually show
– New research on GLP-1s improving liver and kidney health independently of weight loss
– The two-tier benefit model: what the drug does on its own vs. what fat loss adds
– Why body composition — not just the scale — is the metric that matters most
– The lean mass problem: 35–40% of weight lost on GLP-1s can be muscle
– What a truly successful GLP-1 journey looks like in practice
SOURCES
SELECT Trial — Lincoff et al., NEJM 2023 — Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes
SELECT Adiposity Analysis — Deanfield et al., The Lancet 2025 — Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements
SELECT Long-Term Weight Data — Ryan et al., Nature Medicine 2024 — Long-term weight loss effects of semaglutide in SELECT
SELECT Kidney Outcomes — Nature Medicine 2024 — 22% reduction in kidney outcomes in the SELECT cohort
STEP 1 Trial — Wilding et al., NEJM 2021 — Once-Weekly Semaglutide in Adults with Overweight or Obesity
FLOW Trial — Perkovic et al., NEJM 2024 — Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
GLP-1 Liver Mechanisms — Drucker et al., Cell Metabolism 2026 — Semaglutide acts directly on liver sinusoidal endothelial cells independent of weight loss
Cardiovascular Meta-analysis — PMC 2025 — Long-Term Cardiovascular Outcomes of GLP-1 Receptor Agonists in Non-diabetic Obesity
Lean Mass / GLP-1 Meta-analysis — Metabolism: Clinical and Experimental, 2024 — Effect of GLP-1 receptor agonists and co-agonists on body composition
COURAGE Trial (Regeneron) — Interim results, 2024 — Semaglutide-induced weight loss composition data
Visceral Fat Meta-analysis — PLOS ONE, 2023 — Effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat
=======================================================
Affiliate Links (I earn commission for qualifying purchases)
Join Fridays (GLP-1/TRT) Use Code RMZ: joinfridays.com/?via=RMZ
Gruns: grns.sjv.io/AgoLV7
========================================================
Social Links
tiktok.com/@roundmoundofzepbound
instagram.com/roundmoundofzepbound
========================================================
DISCLAIMER: No information provided here is to be construed as medical advice. Always consult with a licensed medical provider for medical advice.
#glp1 #zepbound #mounjaro #weightloss #weightlossjourney #glp #tirzepatide #semaglutide #wegovy #ozempic #menshealth #beforeandafter #beforeandafterweightloss
